One Year of ONCOLOGY RESEARCH AND TREATMENT

Michael Hallek

Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Germany

The journal ONCOLOGY AND RESEARCH AND TREATMENT (formerly called ONKOLOGIE) now exists in its new layout and name for a little more than one year. The journal's name has been changed to English to increase its international visibility. So far, our experience with the new format has been very positive. ONCOLOGY AND RESEARCH AND TREATMENT receives an increasing number of original papers in cancer research. In addition to classical clinical research, also a steadily increasing number of manuscripts dealing with translational research are received. We view this as a very positive development. At the same time, the number of case reports has been strictly limited: in the past year, the journal has accepted only 9 manuscripts with highly relevant paradigm cases that can tell stories of principal value. During the past 12 months we have also accepted 9 manuscripts in the newly installed *fast track peer review*, which is reserved for manuscripts of outstanding excellence. These manuscripts were accepted within an average of less than a month and were selected for immediate free online access by the editor-in-chief. Moreover, the journal will grant free access to all manuscripts after a period of 12 months.

However, also for regular manuscripts, the *average manuscript handling time now is at 2.9 months* from submission to acceptance. First manuscripts start to get cited by colleagues at an international visibility. The highest cited papers since the inception of the new format are:

Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action by Al-Batran, Salah-Eddin; Geissler, Michael; Seufferlein, Thomas; et al. [1].

Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area by Wei, Weihong; Huang, Zeli; Li, Shaoen; et al. [2].

Clinical Benefit Response in Pancreatic Cancer Trials Revisited by Bernhard, Juerg; Dietrich, Daniel; Glimelius, Bengt; et al. [3].

Different scientific medical societies, such as the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OeGHO), the Swiss Society of Hematology (SGH/SSH), the Working Group of Medical Oncology in the German Cancer Society (AIO), and the German Fatigue Society (DFaG) continue to use ONCOLOGY RESEARCH AND TREATMENT as their official journal.

In addition and most importantly, the editorial board is highly committed to establish this journal as one of the leading journals in European cancer research. Taken together, I trust that ONCOLOGY AND RESEARCH AND TREATMENT is on a very good way to further establish itself in the next months.

Cologne, January 2015

Michael Hallek, MD

Editor-in-Chief

References

- 1 Al-Batran SE, Geissler M, Seufferlein T, Oettle H, Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. *Oncol Res Treat* 2014;37:128–134.
- 2 Wei W, Huang Z, Li S, Chen H, Zhang G, Li S, Hu W, Xu T, Pretreatment epstein-barr virus dna load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area. *Oncol Res Treat* 2014;37:88–95.
- 3 Bernhard J, Dietrich D, Glimelius B, Bodoky G, Scheithauer W, Herrmann R, Clinical benefit response in pancreatic cancer trials revisited. *Oncol Res Treat* 2014;37:42–48.